© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#ICAAC 2008
Click Here for More Conferences
Click Here for ICAAC Online
HIV: The Basics
The U.N. General Assembly Hall during the High-level Meeting on HIV/AIDS.

Conferences

High Number of Pulmonary Hypertension Cases in Naval HIV Cohort Study

The incidence of pulmonary hypertension—high blood pressure in the arteries that supply the lungs—is significantly higher in HIV-p...

Drug-Resistant Staph and HIV - Part 2

Tim Horn speaks with researcher Nancy Crum-Cianflone, MD, MPH, about methicillin-resistant Staphylococcus aureus (MRSA)

Drug-Resistant Staph and HIV - Part 1

Tim Horn speaks with Nancy Crum-Cianflone, MD, MPH, a researcher and physician at the Naval Medical Center in San Diego.

Drug-Resistant Staph: Growing Concern Among People With HIV

Skin infections caused by drug-resistant staph are more common and more likely to recur in people living with HIV, according to three new stud...

Truvada vs. Epzicom: The Debate Goes On

A handful of presentations at the 2008 joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the I...

Long-Term Benefits and Risks of Kaletra Monotherapy Explored in Two Studies

More than 10 years after combination HIV treatment was heralded as the one and only way to treat HIV, data continue to emerge suggesting that...

Has HIV Evolved to Become More Dangerous?

Twenty-five years into the HIV epidemic, has the virus evolved to become more dangerous? This was the question asked by a research team headed...

Greater HIV Response to Prezista vs. Kaletra for First-Timers Over 96 Weeks

Once-daily Norvir (ritonavir)-boosted Prezista (darunavir) is more likely to keep viral loads undetectable in HIV-positive people starting ant...

New NNRTI Called RDEA806 Shows Promise

Once-daily RDEA806, an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Ardea Biosciences, appears highl...

Higher Response Rate with Norvir-Boosted Reyataz vs. Kaletra as First-Line Therapy

Long-term follow-up data from a study indicate higher response rates with Norvir (ritonavir)-boosted Reyataz (atazanavir) compared with Kaletr...

PRO 140 Has Long-Lasting Activity Against HIV

Positive early results from a Phase II clinical trial of intravenous (IV) PRO 140, an experimental HIV entry inhibitor.

Selzentry Reanalysis Shows Potential as First-Line Treatment

Selzentry (Celsentri; maraviroc) is comparable to Sustiva (efavirenz) in HIV-positive patients starting antiretroviral (ARV) treatment for the...

Should ARV Treatment Be Started When CD4s Fall Below 500?

New research from a team of U.S. and Canadian researchers suggests that HIV-positive people have less risk of dying if they start ARV...

Isentress Comparable to Sustiva for First-Time Treatment

Isentress (raltegravir) appears to work just as well as Sustiva (efavirenz), with fewer drug-related side effects, in HIV-positive patients st...
Advertisement
Newsfeed
Science News
Features
Opinions

POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.